[Pure red cell aplasia as a complication of treatment with recombinant human erythropoietin].
Due to appearance in the world scientific literature of reports on occurrence of pure red cell aplasia (PRCA) as an adverse effect of treatment with recombinant human erythropoietin administered for anemia correction in the course of chronic renal failure, the paper presents rules of diagnosis and treatment of this complication. PRCA is more frequently observed during subcutaneous administration of erythropoietin a than erythropoietin beta. According to currently available analysis, prophylaxis of PRCA may include changing of the route of erythropoietin alpha administration from subcutaneous to intravenous one.
Grzegorzewska
Alicja E
AE
Katedra i Klinika Nefrologii, Transplantologii i Chorób Wewnetrznych Akademii Medycznej w Poznaniu. alicja_grzegorzewska@yahoo.com
Sucharzewska-Tomczak
Małgorzata
M
D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy
D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D000068817:Epoetin Alfa